Home › Funds › Vestal Point Capital, LP › TRVI
Vestal Point Capital, LP position in TRVI
TREVI THERAPEUTICS INC · Health Care
Vestal Point Capital, LP reported holding 3,100,000 shares of TRVI (TREVI THERAPEUTICS INC) in its Q2 2026 13F filing — a position valued at US$57.8M, representing 1.35% of its reported portfolio and ranking #25 among its reported holdings. Vestal Point Capital, LP has disclosed TRVI holdings in 2 of the last 2 reported quarters, going back to Q1 2026.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How Vestal Point Capital, LP's TRVI position evolved
Vestal Point Capital, LP first disclosed a stake in TRVI in Q1 2026 at 2,166,504 shares (US$25.8M). The position peaked in Q2 2026 at 3,100,000 shares, worth US$57.8M. Across 2 filings, Vestal Point Capital, LP increased the stake 1 time(s), trimmed it 0 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 3,100,000 shares valued at US$57.8M — an increase of 933,496 shares quarter over quarter.. Notable position changes include a 43% increase in Q2 2026 (shares fell 23% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q1 2026 | 2.17M | $25.85M | New |
| Q2 2026 | 3.10M | $57.81M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About TRVI and 13F data
TRVI (TREVI THERAPEUTICS INC) is a Health Care company. 64 other funds we track also report a position in TRVI — the largest reported positions include NEA Management Company, LLC (US$246.6M), Frazier Life Sciences Management, L.P. (US$185.4M), Vivo Capital, LLC (US$95.0M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding TRVI
- NEA Management Company, LLC 13.22M sh · $246.59M · Q2 2026
- Frazier Life Sciences Management, L.P. 9.94M sh · $185.37M · Q2 2026
- Vivo Capital, LLC 5.09M sh · $95.02M · Q2 2026
- MPM BioImpact LLC 3.07M sh · $57.32M · Q2 2026
- EVENTIDE ASSET MANAGEMENT, LLC 2.66M sh · $49.61M · Q2 2026
- Artia Global Partners LP 2.21M sh · $41.23M · Q2 2026
- ACORN CAPITAL ADVISORS, LLC 2.14M sh · $40.00M · Q2 2026
- First Light Asset Management, LLC 2.10M sh · $39.11M · Q2 2026
- Logos Global Management LP 1.88M sh · $35.06M · Q2 2026
- Affinity Asset Advisors, LLC 1.80M sh · $33.57M · Q2 2026
- Siren, L.L.C. 1.79M sh · $33.33M · Q2 2026
- Pivotal bioVenture Partners Investment Advisor LLC 1.74M sh · $32.50M · Q2 2026
More on Vestal Point Capital, LP
FAQ
How long has Vestal Point Capital, LP held TRVI?
Vestal Point Capital, LP has disclosed TRVI holdings in 2 of the last 2 reported quarters, going back to Q1 2026.
What is Vestal Point Capital, LP's current position in TRVI?
As of Q2 2026, Vestal Point Capital, LP holds 3.10M shares of TRVI (TREVI THERAPEUTICS INC), valued at $57.81M, representing 1.35% of its reported portfolio and ranking #25.
Has Vestal Point Capital, LP been buying or selling TRVI?
In the latest 13F filing (Q2 2026), Vestal Point Capital, LP increased its position in TRVI. The position peaked in Q2 2026 at 3.10M shares.
Which other funds hold TRVI?
Other major institutional holders of TRVI include NEA Management Company, LLC, Frazier Life Sciences Management, L.P., Vivo Capital, LLC, among 64 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.